Prolongation of QT interval in isolated feline hearts by antipsychotic drugs

Journal of Clinical Psychopharmacology

Volumn 18, Issue 6, 1998, Pages 477-481

  Drici, Milou Daniel ^a   Wang, Wen X ^a   Liu, Xioa Ke ^a   Woosley, Raymond L ^a   Flockhart, David A ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; POTASSIUM CHANNEL; RISPERIDONE; SERTINDOLE;

ANIMAL TISSUE; ARTICLE; CAT; CONCENTRATION RESPONSE; ELECTROCARDIOGRAM; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; ISOLATED HEART; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; SPECIES DIFFERENCE;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; CATS; CLOZAPINE; ELECTROCARDIOGRAPHY; HALOPERIDOL; HEART; HUMANS; IMIDAZOLES; INDOLES; RISPERIDONE;

EID: 0031730222     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199812000-00011     Document Type: Article

References (39)

1. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J 1986;111:1088-93.
2. The Sicilian gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Circulation 1991;84: 1831-51.
3. Strasberg B, Sclarovsky S, Erdberg A, Duffy CE, Lam W, Swiryn S, Agmon J, Rosen KM. Procainamide-induced polymorphous ventricular tachycardia. Am J Cardiol 1981;47:1309-14.
4. MacConnell TJ, Stanners AJ. Torsades de pointes complicating therapy with terfenadine [letter]. BMJ 1991;302:1469.
5. Wiley JF II, Gelber ML, Henretig FM, Wiley CC, Sandhu S, Loiselle J. Cardiotoxic effects of astemizole overdose in children. J Pediatr 1992;120:799-802.
6. Antzelevitch C, Sun ZQ, Zhang ZQ, Yan GX. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J Am Coll Cardiol 1996;28:1836-948.
7. Donatini B, Le Blaye I, Krupp P. Transient cardiac pacing is insufficiently used to treat arrhythmia associated with thioridazine Cardiology 1992;81:340-1.
8. Fulop G, Phillips RA, Shapiro AK, Gomes JA, Shapiro E, Norlie MA. ECG changes during haloperidol and pimozide treatment for Tourette's disorder. Am J Psychiatry 1987;144:673-5.
9. Metzger E, Friedman R. Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill. J Clin Psychopharmacol 1993;13:128-32.
10. Bigger JT, Giardina EG, Perel JM, Kantor SJ, Glassman AH. Cardiac antiarrhythmic effect of imipramine hydrochloride. N Engl J Med 1977;296:206-8.
11. Flugelman MY, Tal A, Pollack S, Hefez A, Weisstub EB, Gotsman MS, Lewis BS. Psychotropic drugs and long QT syndromes: case reports. J Clin Psychiatry 1985;46:290-1.
12. Fowler NO, McCall D, Chou TC, Holmes JC, Hanenson IB. Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs. Am J Cardiol 1976;37:223-30.
13. Risch SC, Groom GP, Janowsky DS. Effects of psychotropic drugs on the cardiovascular system. J Clin Psychiatry 1982; 43:16-31.
14. Napolitano C, Priori SG, Schwartz PJ. Torsade de pointes: mechanisms and management. Drugs 1994;47:51-65.
15. 2+ channel agonist Bay K 8644. Circ Res 1988;62:563-71.
16. Barnett AA. Safety concerns over antipsychotic drug: sertindole [letter]. Lancet 1996;348:256.
17. Owens DGC. Adverse effects of antipsychotic agents. Drugs 1996;51:895-930.
18. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993;269:1532-6.
19. Drici MD, Burklow TR, Haridasse V, Glazer RI, Woosley RL. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation 1996;94:1471-4.
20. Browne KF, Zipes DP, Heger JJ, Prystowsky EN. Influence of the autonomic nervous system on the QT interval in man. Am J Cardiol 1982;50:1099-103.
21. Woosley RL, Sale M. QT interval: a measure of drug action. Am J Cardiol 1993;72:36B-43B.
22. Pinney SP, Koller BS, Franz MR, Woosley RL. Terfenadine increases the QT interval in isolated guinea pig heart. J Cardiovasc Pharmacol 1995;25:30-4.
23. Franz MR, Bargheer K, Costard Jäckle A, Miller DC, Lichtlen PR. Human ventricular repolarization and T wave genesis. Prog Cardiovasc Dis 1991;33:369-84.
24. Brecher M, Lemmens P, Van Baelen B. Tolerability and cardiovascular safety of risperidone [abstract p. 26]. Presentation at the American College of Neuropsychopharmacology, Dec 9-13, 1996, San Juan, Puerto Rico.
25. Fayer SA. Torsades de pointes ventricular tachyarrhythmia associated with haloperidol. J Clin Psychopharmacol 1986;6:375-6.
26. Metzger E, Friedman R. Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill. J Clin Pharmacol 1993;13:128-32.
27. Mehta D, Mehta S, Petit J, Shriner W. Cardiac arrhythmia and haloperidol. Am J Psychiatry 1979;136:1468-9.
28. Mehtonen O-P, Aranko K, Malkonen L, Zapaatalo H. A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland. Acta Psychiatr Scand 1991; 84:58-64.
29. Zehender M, Hohnloser SH, Just H. QT interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards. Cardiovasc Drug Ther 1991;5:515-30.
30. Roden DM. Early after-depolarizations and torsade de pointes: implications for the control of cardiac arrhythmias by controlling repolarization. Eur Heart J 1993;14[suppl H]:56-61.
31. Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, Van-Raay TJ, Shen J, Timothy KW, Vincent GM, de Jager T, Schwartz PJ, Towbin JA, Moss AJ, Atkinson DL, Landes GM, Conners TD, Keating MT. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet 1996;12:17-23.
32. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995;80:795-803.
33. Kr. Implications for torsade de pointes and reverse-use dependence. Circulation 1996;93:407-11.
34. Tsuang MT, Woolson RF, Fleming JA. Causes of death in schizophrenia and manic depression. Br J Psychiatry 1980;136:239-42.
35. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991;36: 239-45.
36. Carlsson L, Almgren O, Duker G. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions. J Cardiovasc Pharmacol 1990;16:276-85.
37. Roden DM, Lazzara R, Rosen M, Schwartz PJ, Towbin J, Vincent GM. Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation 1996;94:1996-2012.
38. Schinkel AH, Wagenaar E, Mol CAAM, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996;97:2517-24.
39. Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson JL, Moss AJ, Towbin JA, Keating MT. SCN5A mutations associated with an inherited cardiac arrhythmia long QT syndrome. Cell 1995;80: 805-11.